Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC

NCT07155850 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)
Locally Advanced
Unresectable

Interventions

DEVICE: Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas

Sponsor

BetaGlue Therapeutics SpA